MondegarAI
REGENERON PHARMACEUTICALS, INC. (REGN)

Q4 2024 · 13F-HR

REGENERON PHARMACEUTICALS, INC. (REGN)holdings as filed

Filed 2025-02-07 · accession 0001104659-25-010583

$1.09B
Reported value
6
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
02043Q107ALNYAlnylam Pharmaceuticals, Inc.$1.05B95.5%4,444,445CommonSOLE
45826J105NTLAIntellia Therapeutics, Inc.$43.2M3.94%3,702,995CommonSOLE
901384107TSVT*2seventy bio, Inc.$3.7M0.34%1,254,827CommonSOLE
007002108TORCEURAdicet Bio, Inc.$931,3920.09%968,183CommonSOLE
00773U207AVU0Adverum Biotechnologies, Inc.$844,8450.08%180,909CommonSOLE
09609G209BLE0bluebird bio, Inc.$175,1400.02%21,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.